Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Axsome gets broad label for new depression drug; Argenx CEO on Vyvgart’s success; Chinese firms delist from US; solid results for Novo Nordisk’s new diabetes combo; and women leaders herald change at foreign firms in India.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 26 August 2022, including: Axsome Therapeutics, Inc. gets broad label for new depression drug; argenx N.V. CEO on Vyvgart’s success; Chinese firms delist from US; solid results for Novo Nordisk A/S’s new diabetes combo; and women leaders herald change at foreign firms in India.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Axsome’s Wait Pays Off With Broad Auvelity Label For Major Depression" - Scrip, 19 Aug, 2022.)
(Also see "Argenx CEO Shares Secrets Of Vyvgart’s Stellar Success" - Scrip, 22 Aug, 2022.)
(Also see "Delisting Looms As More US-Listed China Companies Seek To Move Closer Home" - Scrip, 23 Aug, 2022.)
(Also see "Novo Nordisk’s New Diabetes Combo Shows Potential To Best Lilly’s Mounjaro" - Scrip, 23 Aug, 2022.)
(Also see "The Old Order Changeth: Women CEOs at Foreign Firms In India Chart New Course" - Scrip, 19 Aug, 2022.)